Free tool
FAERS Monitor: Acular
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019700 or its brand name (Acular, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.
Reports
5,005
Serious
2,966
59% of reports
Hospitalization
1,430
Death reported
295
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective535
- drug hypersensitivity325
- nausea276
- headache267
- pain265
- fatigue251
- dyspnoea240
- treatment failure211
- off label use186
- eye pain183
- vomiting177
- diarrhoea164
- product dose omission issue151
- dizziness147
- eye irritation144
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 59 |
| 2005 | 96 |
| 2006 | 90 |
| 2007 | 80 |
| 2008 | 105 |
| 2009 | 129 |
| 2010 | 119 |
| 2011 | 178 |
| 2012 | 210 |
| 2013 | 81 |
| 2014 | 111 |
| 2015 | 117 |
| 2016 | 378 |
| 2017 | 244 |
| 2018 | 226 |
| 2019 | 320 |
| 2020 | 512 |
| 2021 | 245 |
| 2022 | 323 |
| 2023 | 381 |
| 2024 | 363 |
| 2025 | 376 |
| 2026 | 262 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,154 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 183 | 13.7 | 11.9 | 2,135 |
| treatment failureSignal | 211 | 10.7 | 9.4 | 1,854 |
| eye irritationSignal | 144 | 10.5 | 9.0 | 1,234 |
| drug hypersensitivitySignal | 325 | 7.1 | 6.4 | 1,700 |
| product dose omission issueSignal | 151 | 2.2 | 1.8 | 94 |
| pain | 265 | 1.8 | 1.6 | 99 |
| headache | 267 | 1.8 | 1.6 | 95 |
| dyspnoea | 240 | 1.8 | 1.6 | 84 |
| drug ineffective | 535 | 1.7 | 1.6 | 166 |
| vomiting | 177 | 1.6 | 1.4 | 38 |
| nausea | 276 | 1.5 | 1.3 | 42 |
| fatigue | 251 | 1.4 | 1.2 | 24 |
| dizziness | 147 | 1.2 | 1.1 | 7 |
| diarrhoea | 164 | 1.1 | 0.9 | 1 |
| off label use | 186 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.